
Todd A Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8913696/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet, The, 2007, 370, 741-750.	13.7	1,818
2	Multiple Chronic Conditions: Prevalence, Health Consequences, and Implications for Quality, Care Management, and Costs. Journal of General Internal Medicine, 2007, 22, 391-395.	2.6	896
3	The Economic Burden of COPD. Chest, 2000, 117, 5S-9S.	0.8	507
4	Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Medicine, 2007, 5, 20.	5.5	334
5	The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and Design. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 277-283.	1.6	256
6	The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999–2008. BMC Pulmonary Medicine, 2012, 12, 26.	2.0	212
7	Lower-Extremity Amputation Risk After Charcot Arthropathy and Diabetic Foot Ulcer. Diabetes Care, 2010, 33, 98-100.	8.6	186
8	The Economic Burden of Allergic Rhinitis. Pharmacoeconomics, 2004, 22, 345-361.	3.3	182
9	Assessment of the emergence of Alzheimer's disease following coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty1. Journal of Alzheimer's Disease, 2005, 7, 319-324.	2.6	171
10	Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary Disease. Annals of Internal Medicine, 2008, 149, 380.	3.9	151
11	Mortality Risk of Charcot Arthropathy Compared With That of Diabetic Foot Ulcer and Diabetes Alone. Diabetes Care, 2009, 32, 816-821.	8.6	147
12	â€~Pharmacy Deserts' Are Prevalent In Chicago's Predominantly Minority Communities, Raising Medication Access Concerns. Health Affairs, 2014, 33, 1958-1965.	5.2	141
13	Mortality Rate in Veterans with Multiple Chronic Conditions. Journal of General Internal Medicine, 2007, 22, 403-7.	2.6	127
14	Use of a preference-based measure of health (EQ-5D) in COPD and asthma. Respiratory Medicine, 2008, 102, 519-536.	2.9	126
15	The Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Diagnosis Codes for Identifying Patients Hospitalized for COPD Exacerbations. Chest, 2012, 141, 87-93.	0.8	122
16	Spirometry Use in Clinical Practice Following Diagnosis of COPD. Chest, 2006, 129, 1509-1515.	0.8	120
17	The validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease. BMC Health Services Research, 2011, 11, 37.	2.2	116
18	Cardiovascular Events Associated With Ipratropium Bromide in COPD. Chest, 2010, 137, 13-19.	0.8	100

#	Article	IF	CITATIONS
19	Fracture Risk Associated with Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 855-859.	5.6	92
20	Asthma outcomes: Healthcare utilization and costs. Journal of Allergy and Clinical Immunology, 2012, 129, S49-S64.	2.9	88
21	The risk of seizures among the carbapenems: a meta-analysis. Journal of Antimicrobial Chemotherapy, 2014, 69, 2043-2055.	3.0	84
22	Charcot Arthropathy Risk Elevation in the Obese Diabetic Population. American Journal of Medicine, 2008, 121, 1008-1014.	1.5	80
23	Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective. Lancet Respiratory Medicine,the, 2016, 4, 473-526.	10.7	80
24	Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis. Journal of Antimicrobial Chemotherapy, 2009, 63, 816-825.	3.0	74
25	Realâ€World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation. Pharmacotherapy, 2017, 37, 1221-1230.	2.6	74
26	Comparison of health-related quality of life measures in chronic obstructive pulmonary disease. Health and Quality of Life Outcomes, 2011, 9, 26.	2.4	73
27	Using A Pharmacy-Based Intervention To Improve Antipsychotic Adherence Among Patients With Serious Mental Illness. Schizophrenia Bulletin, 2011, 37, 727-736.	4.3	73
28	Geographic Variation of Spirometry Use in Newly Diagnosed COPD*. Chest, 2008, 134, 38-45.	0.8	68
29	Impact of Pneumococcal Vaccination on Pneumonia Rates in Patients with COPD and Asthma. Journal of General Internal Medicine, 2007, 22, 62-67.	2.6	64
30	A Multisite Randomized Trial of the Effects of Physician Education and Organizational Change in Chronic Asthma Care. JAMA Pediatrics, 2005, 159, 428.	3.0	62
31	Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respiratory Medicine, 2010, 104, 246-252.	2.9	62
32	Home-based Diagnosis of Obstructive Sleep Apnea in an Urban Population. Journal of Clinical Sleep Medicine, 2014, 10, 879-885.	2.6	62
33	Development of the multi-attribute Pediatric Asthma Health Outcome Measure (PAHOM). International Journal for Quality in Health Care, 2005, 17, 23-30.	1.8	58
34	Association Between Rising Professional Liability Insurance Premiums and Primary Cesarean Delivery Rates. Obstetrics and Gynecology, 2007, 110, 1264-1269.	2.4	57
35	Sixtyâ€four–slice Computed Tomography of the Coronary Arteries: Cost–Effectiveness Analysis of Patients Presenting to the Emergency Department with Lowâ€risk Chest Pain. Academic Emergency Medicine, 2008, 15, 623-632.	1.8	57
36	Vitamin D Deficiency/Insufficiency Practice Patterns in a Veterans Health Administration Long-Term Care Population: A Retrospective Analysis. Journal of the American Medical Directors Association, 2009, 10, 653-657.	2.5	55

#	Article	IF	CITATIONS
37	Significant Jâ€shaped association between body mass index (BMI) and diabetic foot ulcers. Diabetes/Metabolism Research and Reviews, 2011, 27, 402-409.	4.0	52
38	Risk of amputations associated with SGLT2 inhibitors compared to DPPâ€4 inhibitors: A propensityâ€matched cohort study. Diabetes, Obesity and Metabolism, 2018, 20, 2792-2799.	4.4	52
39	Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?. Health and Quality of Life Outcomes, 2005, 3, 11.	2.4	51
40	Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: AÂnested case-control study. Journal of Allergy and Clinical Immunology, 2012, 130, 368-375.	2.9	51
41	Cost of Chronic Hepatitis B Infection in the United States. Journal of Clinical Gastroenterology, 2004, 38, S144-S147.	2.2	49
42	Use of Spirometry in the Diagnosis of COPD: A Qualitative Study in Primary Care. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 444-449.	1.6	49
43	The societal cost of heroin use disorder in the United States. PLoS ONE, 2017, 12, e0177323.	2.5	48
44	Medication adherence and persistence in the last year of life in COPD patients. Respiratory Medicine, 2009, 103, 525-534.	2.9	47
45	Multicenter Study Comparing Case Definitions Used to Identify Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 989-995.	5.6	47
46	Outcomes Associated With Tiotropium Use in Patients With Chronic Obstructive Pulmonary Disease. Archives of Internal Medicine, 2009, 169, 1403.	3.8	46
47	Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form. BMC Medical Research Methodology, 2014, 14, 78.	3.1	46
48	Coexisting chronic conditions associated with mortality and morbidity in adult patients with asthma. Journal of Asthma, 2014, 51, 306-314.	1.7	44
49	Association between Leukotriene-Modifying Agents and Suicide. Drug Safety, 2011, 34, 533-544.	3.2	43
50	Statin use and lower extremity amputation risk in nonelderly diabetic patients. Journal of Vascular Surgery, 2013, 58, 1578-1585.e1.	1.1	42
51	Tumor necrosis factorâ€alpha inhibitors and risk of nonâ€Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. International Journal of Cancer, 2018, 143, 1062-1071.	5.1	42
52	Hospitalizations for Acute Exacerbations of Chronic Obstructive Pulmonary Disease: How You Count Matters. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2010, 7, 164-171.	1.6	41
53	Determinants of Spirometry Use and Accuracy of COPD Diagnosis in Primary Care. Journal of General Internal Medicine, 2011, 26, 1272-1277.	2.6	41
54	Association Between Proton Pump Inhibitors and Microscopic Colitis. Annals of Pharmacotherapy, 2017, 51, 253-263.	1.9	39

Todd A Lee

#	Article	IF	CITATIONS
55	Stakeholder Priorities for Comparative Effectiveness Research in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 320-326.	5.6	38
56	The association of opioid use with incident lower extremity fractures in spinal cord injury. Journal of Spinal Cord Medicine, 2013, 36, 91-96.	1.4	37
57	Reduced Overall and Event-Free Survival among Colon Cancer Patients Using Dual System Care. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2231-2241.	2.5	35
58	Trends in induction of labor at early-term gestation. American Journal of Obstetrics and Gynecology, 2011, 204, 435.e1-435.e6.	1.3	34
59	Development, validation, and results of a riskâ€standardized measure of hospital 30â€day mortality for patients with exacerbation of chronic obstructive pulmonary disease. Journal of Hospital Medicine, 2013, 8, 428-435.	1.4	34
60	Drug–Alcohol Interactions in Older U.S. Adults. Journal of the American Geriatrics Society, 2015, 63, 2324-2331.	2.6	34
61	Economic Modeling in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2006, 3, 630-634.	3.5	31
62	Effect of Care Setting on Evidence-based Depression Treatment for Veterans with COPD and Comorbid Depression. Journal of General Internal Medicine, 2007, 22, 1447-1452.	2.6	30
63	Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections. International Journal of Clinical Pharmacy, 2014, 36, 1282-1289.	2.1	30
64	Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 57-63.	0.9	29
65	Comparison of Directly Elicited Preferences to Preferences Derived from the SF-36 in Adults with Asthma. Medical Decision Making, 2003, 23, 323-334.	2.4	28
66	Impact of NSAIDS on Mortality and the Effect of Preexisting Coronary Artery Disease in US Veterans. American Journal of Medicine, 2007, 120, 98.e9-98.e16.	1.5	28
67	Meta-Analysis of Azelastine Nasal Spray for the Treatment of Allergic Rhinitis. Pharmacotherapy, 2007, 27, 852-859.	2.6	28
68	Effect of Depression Care on Outcomes in COPD Patients With Depression. Chest, 2009, 135, 626-632.	0.8	28
69	Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature. Paediatric Drugs, 2017, 19, 21-34.	3.1	28
70	Diagnostic accuracy of existing methods for identifying diabetic foot ulcers from inpatient and outpatient datasets. Journal of Foot and Ankle Research, 2010, 3, 27.	1.9	27
71	Medication acquisition across systems of care and patient–provider communication among older veterans. American Journal of Health-System Pharmacy, 2013, 70, 804-813.	1.0	26
72	Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. Medical Decision Making, 2018, 38, 968-982.	2.4	25

#	Article	IF	CITATIONS
73	Osteoarthritis: A Comorbid Marker for Longer Life?. Annals of Epidemiology, 2007, 17, 380-384.	1.9	24
74	Geographic Variation in Chronic Obstructive Pulmonary Disease Exacerbation Rates. Journal of General Internal Medicine, 2007, 22, 1560-1565.	2.6	24
75	Mortality Risk in Patients Receiving Drug Regimens with Theophylline for Chronic Obstructive Pulmonary Disease. Pharmacotherapy, 2009, 29, 1039-1053.	2.6	23
76	Use of spirometry in the diagnosis of chronic obstructive pulmonary disease and efforts to improve quality of care. Translational Research, 2009, 154, 103-110.	5.0	23
77	Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis. Rheumatology, 2018, 57, 273-282.	1.9	23
78	A Patient-Based Utility Measure of Health for Clinical Trials of Cancer Therapy Based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. Value in Health, 2009, 12, 977-988.	0.3	22
79	High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy. Journal of Thrombosis and Thrombolysis, 2017, 44, 435-441.	2.1	22
80	Increased risk of mycotic infections associated with sodium–glucose coâ€ŧransporter 2 inhibitors: a prescription sequence symmetry analysis. British Journal of Clinical Pharmacology, 2019, 85, 160-168.	2.4	22
81	Chronic Heart Failure–Related Interventions After Starting Rosiglitazone in Patients Receiving Insulin. Pharmacotherapy, 2004, 24, 1317-1322.	2.6	21
82	Three Surveillance Strategies for Vancomycin-Resistant Enterococci in Hospitalized Patients: Detection of Colonization Efficiency and a Cost-Effectiveness Model. Infection Control and Hospital Epidemiology, 2005, 26, 39-46.	1.8	21
83	Effect of Increased Copayments on Pharmacy Use in the Department of Veterans Affairs. Medical Care, 2007, 45, 1090-1097.	2.4	21
84	Drugs Associated with Adverse Events in Children and Adolescents. Pharmacotherapy, 2014, 34, 918-926.	2.6	21
85	Sodiumâ€glucose coâ€transporter 2 inhibitors and the risk of fractures: A propensity scoreâ€matched cohort study. Pharmacoepidemiology and Drug Safety, 2019, 28, 1629-1639.	1.9	21
86	Impact of asthma controller medications on medical and economic resource utilization in adult asthma patients. Current Medical Research and Opinion, 2010, 26, 2851-2860.	1.9	19
87	The Association of Anticonvulsant Use with Fractures in Spinal Cord Injury. American Journal of Physical Medicine and Rehabilitation, 2013, 92, 1037-1050.	1.4	19
88	Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting β2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid. Annals of Pharmacotherapy, 2017, 51, 945-953.	1.9	19
89	Obstetricians' Rising Liability Insurance Premiums and Inductions at Late Preterm Gestations. Medical Care, 2009, 47, 425-430.	2.4	18
90	Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review. Pharmacoeconomics, 2014, 32, 1079-1091.	3.3	18

#	Article	IF	CITATIONS
91	Comparative Effectiveness of Long-Acting Beta ₂ -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease. Pharmacotherapy, 2017, 37, 447-455.	2.6	18
92	Patterns of Healthcare Utilization by COPD Severity: A Pilot Study. Lung, 2008, 186, 307-312.	3.3	17
93	Capitalizing on Prescribing Pattern Variation to Compare Medications for Type 2 Diabetes. Value in Health, 2014, 17, 854-862.	0.3	17
94	Statistical implications of utility weighted and equally weighted HRQL measures: an empirical study. Health Economics (United Kingdom), 2010, 19, 101-110.	1.7	16
95	Risk factors and outcomes associated with vancomycin-resistant Enterococcus infections with reduced susceptibilities to linezolid. Diagnostic Microbiology and Infectious Disease, 2012, 74, 39-42.	1.8	16
96	Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data. Annals of the American Thoracic Society, 2016, 13, 1067-1075.	3.2	16
97	Statin and Aspirin Use Among Hispanic and Latino Adults at High Cardiovascular Risk: Findings From the Hispanic Community Health Study/Study of Latinos. Journal of the American Heart Association, 2016, 5, e002905.	3.7	16
98	Agreement between Caregiver Reported Healthcare Utilization and Administrative Data for Children with Asthma. Journal of Asthma, 2007, 44, 189-194.	1.7	15
99	Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002–2008. Supportive Care in Cancer, 2012, 20, 1649-1657.	2.2	15
100	Sensitization to mouse and cockroach allergens and asthma morbidity in urban minority youth. Annals of Allergy, Asthma and Immunology, 2016, 117, 43-49.e1.	1.0	15
101	Top-down Versus Step-up Prescribing Strategies for Tumor Necrosis Factor Alpha Inhibitors in Children and Young Adults with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 2410-2417.	1.9	15
102	Cost-effectiveness of influenza vaccination of older adults in the ED setting. American Journal of Emergency Medicine, 2012, 30, 1072-1079.	1.6	14
103	Surgery and Adjuvant Chemotherapy Use Among Veterans With Colon Cancer: Insights From a California Study. Journal of Clinical Oncology, 2010, 28, 2571-2576.	1.6	13
104	Reply: Association Between Proton Pump Inhibitors and Microscopic Colitis: Implications for Practice and Future Research. Annals of Pharmacotherapy, 2017, 51, 719-719.	1.9	13
105	Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A crossâ€sectional analysis of the National Health and Nutrition Examination Survey. Journal of Diabetes, 2020, 12, 385-395.	1.8	13
106	Appropriateness of Medication Prescribing Using the STOPP/START Criteria in Veterans Receiving Home-Based Primary Care. The Consultant Pharmacist, 2013, 28, 361-369.	0.4	12
107	Risk of Arrhythmias Associated with Ipratropium Bromide in Children, Adolescents, and Young Adults with Asthma: A Nested Caseâ€Control Study. Pharmacotherapy, 2014, 34, 315-323.	2.6	12
108	Comparison of Health Care Utilization and Costs for Patients with Asthma by Severity and Health Insurance in Thailand. Value in Health Regional Issues, 2016, 9, 105-111.	1.2	12

#	Article	IF	CITATIONS
109	Identification of barriers to safe opioid prescribing in primary care: a qualitative analysis of field notes collected through academic detailing. British Journal of General Practice, 2020, 70, e589-e597.	1.4	12
110	Relationship between leukotriene-modifying agent prescriptions dispensed and rate of suicide deaths by county in the US. Drug, Healthcare and Patient Safety, 2011, 3, 47.	2.5	11
111	Comparative effectiveness research in chronic obstructive pulmonary disease. Journal of Comparative Effectiveness Research, 2012, 1, 71-82.	1.4	11
112	Thiazide Use Is Associated With Reduced Risk for Incident Lower Extremity Fractures in Men With Spinal Cord Injury. Archives of Physical Medicine and Rehabilitation, 2014, 95, 1015-1020.	0.9	11
113	Complexity of Medication Use in Newly Diagnosed Chronic Obstructive Pulmonary Disease Patients. American Journal of Geriatric Pharmacotherapy, 2012, 10, 110-122.e1.	3.0	10
114	Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis. Pharmacotherapy, 2016, 36, 1201-1209.	2.6	10
115	Patient Experience-based Value Sets. Medical Care, 2017, 55, 979-984.	2.4	10
116	Older Medicare Beneficiaries Frequently Continue Medications with Limited Benefit Following Hospice Admission. Journal of General Internal Medicine, 2019, 34, 2029-2037.	2.6	10
117	Feasibility and acceptability of virtual academic detailing on opioid prescribing. International Journal of Medical Informatics, 2021, 147, 104365.	3.3	10
118	Risk of Serious Bacterial Infection Associated With Tumor Necrosis Factor–Alpha Inhibitors in Children and Young Adults With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 883-891.	1.9	9
119	Racial Disparities in Term Induction of Labor Rates in Illinois. Medical Care, 2008, 46, 900-904.	2.4	8
120	National trends and racial differences in late preterm induction. American Journal of Obstetrics and Gynecology, 2011, 205, 458.e1-458.e7.	1.3	8
121	Predicting Acute Exacerbations in Chronic Obstructive Pulmonary Disease. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 265-279.	0.9	8
122	Trend in Tyrosine Kinase Inhibitor Utilization, Price, and Out-of-Pocket Costs in Patients With Chronic Myelogenous Leukemia. JCO Oncology Practice, 2021, 17, e1811-e1820.	2.9	8
123	The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and Design. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 277-283.	1.6	8
124	A Review of the Utility and Cost Effectiveness of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. Managed Care, 2018, 27, 34-41.	0.3	8
125	Trends in Opioid Prescribing by General Dentists and Dental Specialists in the U.S., 2012–2019. American Journal of Preventive Medicine, 2022, 63, 3-12.	3.0	8
126	An update on the health economics of asthma and allergy. Current Opinion in Allergy and Clinical Immunology, 2002, 2, 195-200.	2.3	7

#	Article	IF	CITATIONS
127	Medication Use Patterns Associated with Spirometry in Diagnosing COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 360-368.	1.6	7
128	Comparative Effectiveness of Paricalcitol versus Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. Nephron Clinical Practice, 2011, 117, c151-c159.	2.3	7
129	Understanding medication oversupply and its predictors in the outpatient departments in Thailand. BMC Health Services Research, 2014, 14, 408.	2.2	7
130	Association Between Chronic Illness Complexity and Receipt of Evidence-based Depression Care. Medical Care, 2014, 52, S126-S131.	2.4	7
131	Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome. Pharmacotherapy, 2017, 37, 877-887.	2.6	7
132	Practice change intentions after academic detailing align with subsequent opioid prescribing. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 1001-1008.	1.5	7
133	Racial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare. JCO Oncology Practice, 2021, 17, e294-e312.	2.9	7
134	The Association Between Leukotriene-Modifying Agents and Spontaneously Reported Suicide. Drug Information Journal, 2012, 46, 99-106.	0.5	6
135	Calendar timeâ€specific propensity score analysis for observational data: a case study estimating the effectiveness of inhaled longâ€acting betaâ€agonist on asthma exacerbations. Pharmacoepidemiology and Drug Safety, 2014, 23, 152-164.	1.9	6
136	Medicare Part D Use of Older Medicare Beneficiaries Admitted to Hospice. Journal of the American Geriatrics Society, 2018, 66, 937-944.	2.6	6
137	The impact of depression medications on oral antidiabetic drug adherence in patients with diabetes and depression. Journal of Diabetes and Its Complications, 2018, 32, 492-500.	2.3	6
138	Use of Nonpalliative Medications Following Burdensome Health Care Transitions in Hospice Patients. Medical Care, 2019, 57, 13-20.	2.4	6
139	Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers. Journal of Medical Economics, 2020, 23, 132-138.	2.1	6
140	Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 67-75.	0.9	6
141	Comparison of Cardiac Events Associated With Azithromycin vs Amoxicillin. JAMA Network Open, 2020, 3, e2016864.	5.9	6
142	Targets of biologic diseaseâ€modifying antirheumatic drugs and risk of multiple myeloma. International Journal of Cancer, 2020, 147, 1300-1305.	5.1	6
143	Antibiotic Prescribing for Acute Respiratory Infection and Subsequent Outpatient and Hospital Utilization in Veterans With Spinal Cord Injury and Disorder. PM and R, 2010, 2, 101-109.	1.6	5
144	Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis. American Journal of Health-System Pharmacy, 2021, 78, 697-704.	1.0	5

#	Article	IF	CITATIONS
145	Preference assessment in patients with asthma. Expert Review of Pharmacoeconomics and Outcomes Research, 2002, 2, 607-618.	1.4	4
146	Evaluation of changes in guidelines for medication management of stable chronic obstructive pulmonary disease. Journal of Evaluation in Clinical Practice, 2012, 19, n/a-n/a.	1.8	4
147	Hemoglobin Levels Triggering Erythropoiesis‣timulating Agent Therapy in Patients with Cancer: the Shift After United States Food and Drug Administration Policy Changes. Pharmacotherapy, 2012, 32, 988-997.	2.6	4
148	Cost-utility of chelators in transfusion-dependent Î ² -thalassemia major patients: a review of the pharmacoeconomic literature. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 651-660.	1.4	4
149	Impact of adverse event reports from marketing authorization holder-sponsored patient support programs on the performance of signal detection in pharmacovigilance. Expert Opinion on Drug Safety, 2020, 19, 1357-1366.	2.4	4
150	Exploring Completeness of Adverse Event Reports as a Tool for Signal Detection in Pharmacovigilance. Therapeutic Innovation and Regulatory Science, 2021, 55, 142-151.	1.6	4
151	Life-Years Gained with Meropenem over Ciprofloxacin in Penicillin-Allergic Patients with Gram-Negative Bacilli Sepsis: Results of a Probabilistic Model. Pharmacotherapy, 2011, 31, 469-479.	2.6	3
152	Outpatient influenza antiviral prescription trends with influenza-like illness in the USA, 2008–2010. International Journal of Antimicrobial Agents, 2014, 43, 279-283.	2.5	3
153	Reply. Journal of Vascular Surgery, 2014, 59, 876.	1.1	3
154	Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 800-812.	0.9	3
155	Risk of Diabetes Hospitalization or Diabetes Drug Intensification in Patients With Depression and Diabetes Using Second-Generation Antipsychotics Compared to Other Depression Therapies. primary care companion for CNS disorders, The, 2018, 20, .	0.6	3
156	Using linked electronic data to validate algorithms for health outcomes in administrative databases. Journal of Comparative Effectiveness Research, 2015, 4, 359-366.	1.4	2
157	Increased Risk of Diabetes Among 6–24-Year-Olds Using Second Generation Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 782-791.	1.3	2
158	Hospitalizations for opioidâ€related overdose and timing of concurrent opioid and benzodiazepine use: A nested caseâ€control study. Pharmacotherapy, 2021, 41, 722-732.	2.6	2
159	Development of a measure of prescriber satisfaction with academic detailing: the PSAD. Drugs in Context, 2022, 11, 1-12.	2.2	2
160	Combating the opioid epidemic in the United States. Drugs in Context, 2021, 10, 1-3.	2.2	2
161	Cost-effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease. American Journal of Medicine, 2004, 117, 618.	1.5	1
162	Coded Cause of Death and Timing of COPD Diagnosis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2009, 6, 41-47.	1.6	1

#	Article	IF	CITATIONS
163	Defining an Episode of Care for Colonoscopy: Work of the High Value Health Care Project Characterizing Episodes and Costs of Care. Gastrointestinal Endoscopy Clinics of North America, 2010, 20, 735-750.	1.4	1
164	Secondary Effects of an Opioid-Focused Academic Detailing Program on Non-Opioid Controlled Substance Prescribing in Primary Care. Substance Abuse, 2021, 42, 962-967.	2.3	1
165	Risk of fallâ€related injury and allâ€cause hospitalization of select concomitant central nervous system medication prescribing in older adult persistent opioid users: A caseâ€timeâ€control analysis. Pharmacotherapy, 2021, 41, 733-742.	2.6	1
166	Tumor Necrosis Factor-Alpha Inhibitor Medications for Inflammatory Conditions and Incidence of Multiple Myeloma. Blood, 2015, 126, 2954-2954.	1.4	1
167	Health care resource utilization in patients with advanced melanoma receiving immunotherapies in the real world Journal of Clinical Oncology, 2019, 37, 9532-9532.	1.6	1
168	Evaluating the efficiency of treatment in the allergic rhinitis market. Journal of Managed Care Pharmacy, 2004, 10, S3-8.	2.2	1
169	Consensus. Clinical Pulmonary Medicine, 2005, 12, S22-S23.	0.3	0
170	Safety of Ipratropium Bromide: Response. Chest, 2010, 138, 235-236.	0.8	0
171	Comparative Analysis of Calendar Time-Specific and Conventional Propensity Score Analysis for Thiazolidinedione Use in Diabetes. Value in Health Regional Issues, 2014, 3, 222-228.	1.2	0
172	Risk of cardiac events with azithromycin—A prediction model. PLoS ONE, 2020, 15, e0240379.	2.5	0
173	Lung and colon cancer costs among chemotherapy patients after an FDA policy change Journal of Clinical Oncology, 2013, 31, e14578-e14578.	1.6	0
174	Venous Thromboembolic Prophylaxis Following Treatment Initiation for Multiple Myeloma. Blood, 2018, 132, 4693-4693.	1.4	0
175	Biologic Disease-Modifying Antirheumatic Drugs and Risk of Multiple Myeloma. Blood, 2018, 132, 1888-1888.	1.4	0
176	Risk of cardiac events with azithromycinâ \in "A prediction model. , 2020, 15, e0240379.		0
177	Risk of cardiac events with azithromycin—A prediction model. , 2020, 15, e0240379.		0
178	Risk of cardiac events with azithromycin—A prediction model. , 2020, 15, e0240379.		0
179	Risk of cardiac events with azithromycin—A prediction model. , 2020, 15, e0240379.		0
180	Barriers to and facilitators of opioid prescribing by dentists in the United States. Journal of the American Dental Association, 2022, , .	1.5	0